Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEP1B | Q16820 | 7/20 | 0.65 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.56 |
| ▸ | MYC | P01106 | 1/20 | 0.56 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.55 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | MRGPRX4 | Q96LA9 | 4/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.51 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.51 |
| ▸ | RELA | Q04206 | 1/20 | 0.51 |
| ▸ | UNG | P13051 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30444148 | 1.00 | MEP1B (0.65) | MEP1BFOLH1MYCNR1H4CA1 | |
| SCHEMBL6906260 | 0.86 | MEP1B (0.49) | MEP1BMYCSMN1; SMN2 | |
| SCHEMBL13660508 | 0.85 | MEP1B (0.60) | MEP1BFOLH1MYCNR1H4CA1 | |
| Isophthalic Acid SCHEMBL459728 | 0.83 | CA12 (0.52) | MEP1BFOLH1CA1CA2PKM | |
| SCHEMBL14143797 | 0.83 | LOXL2 (0.64) | MEP1BFOLH1MRGPRX4HIF1ASMN1; SMN2 | |
| SCHEMBL805218 | 0.82 | MEP1B (0.59) | MEP1BFOLH1NR1H4MRGPRX4HIF1A | |
| SCHEMBL30444058 | 0.82 | MEP1B (0.59) | MEP1BFOLH1NR1H4MRGPRX4HIF1A | |
| SCHEMBL22668307 | 0.82 | MEP1B (0.46) | MEP1BMYCCA2SMN1; SMN2 | |
| SCHEMBL14793785 | 0.81 | MEP1B (0.63) | MEP1BFOLH1MYCNR1H4CA1 | |
| SCHEMBL991080 | 0.80 | FOLH1 (0.61) | FOLH1MRGPRX4HIF1ASMN1; SMN2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9662339-B2 | Benzodioxane inhibitors of leukotriene production for combination therapy | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-05-30 | — | — | US | disclosed |
| EP-2822941-B1 | BENZODIOXANES IN COMBINATION WITH STATINS FOR INHIBITING LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INT (DE) | 2017-05-10 | — | — | EP | disclosed |
| US-9199927-B2 | Guanidinobenzoic acid compound | ASTELLAS PHARMA INC. (JP) | 2015-12-01 | — | — | US | disclosed |
| US-20140378459-A1 | GUANIDINOBENZOIC ACID COMPOUND | ASTELLAS PHARMA INC. (JP) | 2014-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140378459-A1 | GUANIDINOBENZOIC ACID COMPOUND | SERPINB1, REN, SPINT2 | MEP1B 412/4885FOLH1 689/4885MYC 4814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.